Akeso (09926.HK) announced that the company's independently developed global first bispecific antibody, Idoxifor (known as Ivosidenib, PD-1/VEGF), a single-agent first-line treatment for locally advanced or metastatic non-small cell lung cancer with positive PD-L1 expression, has been officially accepted by the China Food and Drug Administration for listing application. Currently, Ivosidenib has obtained one indication approval in Mainland China, and five phase III clinical studies are underway.
康方生物(09926.HK)依達方新適應症上市申請獲正式受理
Akeso (09926.HK)'s new application for indication of Iduvance has been officially accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.